Biogen (BIIB) Tops Q4 EPS by 3c; offers outlook
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.74 -2.93%
Revenue Growth %: -6.5%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: -6.5%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $3.44, $0.03 better than the analyst estimate of $3.41. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.41 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $15.25-$16.25, versus the consensus of $16.24.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- Culp, Inc. (CULP) Misses Q4 EPS by 12c
- FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
